Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Community Bank & Trust Waco Texas

Community Bank & Trust Waco Texas trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,526 shares of the medical equipment provider’s stock after selling 275 shares during the period. Community Bank & Trust Waco Texas’ holdings in Zimmer Biomet were worth $584,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BLB&B Advisors LLC grew its stake in Zimmer Biomet by 2.1% in the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after buying an additional 100 shares during the last quarter. CKW Financial Group grew its position in shares of Zimmer Biomet by 11.7% in the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares during the last quarter. FWG Holdings LLC increased its stake in shares of Zimmer Biomet by 2.9% in the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after purchasing an additional 101 shares during the period. Romano Brothers AND Company lifted its position in shares of Zimmer Biomet by 1.1% during the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock worth $1,000,000 after purchasing an additional 102 shares during the last quarter. Finally, Financial Advocates Investment Management grew its holdings in Zimmer Biomet by 3.5% in the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after buying an additional 103 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $100.40 on Tuesday. The stock has a 50-day simple moving average of $107.34 and a 200 day simple moving average of $108.07. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $99.67 and a 12-month high of $133.90. The stock has a market capitalization of $19.99 billion, a price-to-earnings ratio of 22.56, a P/E/G ratio of 1.83 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business earned $2.20 earnings per share. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. Zimmer Biomet’s dividend payout ratio is 21.57%.

Wall Street Analyst Weigh In

ZBH has been the subject of several research reports. Barclays reduced their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday. JMP Securities restated a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Friday. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, Truist Financial reaffirmed a “hold” rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.